A Phase 2b, Randomised, Double-blind, Placebo-controlled, Parallel-arm, Multicenter Study Evaluating the Safety and Efficacy of Tesnatilimab in Patients with Moderately to Severely Active Crohn’s DiseaseMatthieu Allez, Taku Kobayashi, Bin Zou et al.|Journal of Crohn s and Colitis|2023Cited by 11
689 Early Improvement After Intravenous Ustekinumab Induction in Patients With Ulcerative Colitis: Results From the UNIFI Induction TrialBruce E. Sands, Silvio Danese, María T. Abreu et al.|The American Journal of Gastroenterology|2019Cited by 3
832 Pharmacokinetics and Exposure-Response Relationships of Ustekinumab in Patients With Ulcerative Colitis: Results From the UNIFI Induction and Maintenance StudiesOmoniyi J. Adedokun, William J. Sandborn, Bruce E. Sands et al.|The American Journal of Gastroenterology|2019Cited by 2